Home > Riviste > Minerva Ginecologica > Fascicoli precedenti > Minerva Ginecologica 2017 April;69(2) > Minerva Ginecologica 2017 April;69(2):160-70

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

MINERVA GINECOLOGICA

Rivista di Ostetricia e Ginecologia


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEW  


Minerva Ginecologica 2017 April;69(2):160-70

DOI: 10.23736/S0026-4784.16.04007-7

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

New options for menopausal symptoms after 15 years of WHI Study

Santiago PALACIOS 1, Pluvio J. CORONADO 2

1 Director of Instituto Palacios, Madrid, Spain; 2 Department of Obstetrics and Gynecology, San Carlos Clinic Hospital, Madrid, Spain


PDF  


Menopausal symptoms include vasomotor symptoms (VMS), vulvar-vaginal atrophy, and loss of bone mass associated with an increased risk of fracture. Treatment of VMS consists of lifestyle changes, hormone treatment (estrogens with and without progestogens, tissue selective estrogens complex or conjugated estrogens and bazedoxifene [CE/BZA], progestogens, and tibolone), and nonhormonal treatments. Genitourinary symptoms due to vulvar-vaginal atrophy are treated with systemic and local hormones, moisturizer creams and gels, CE/BZA, and a selective estrogen receptor modulator (ospemifene). In addition to lifestyle changes, treatments for the risk of fragility fracture include calcium and vitamin D, hormone treatment, selective estrogen receptor modulators (raloxifene, BZA), bisphosphonates, strontium ranelate, denosumab, and teriparatide. This article reviews treatment options and provides treatment algorithms for women with menopausal symptoms.


KEY WORDS: Vulva - Atrophy - Fractures, bone - Risk - Therapeutics - Menopause

inizio pagina

Publication History

Issue published online: January 30, 2017
Article first published online: December 14, 2016

Per citare questo articolo

Palacios S, Coronado PJ. New options for menopausal symptoms after 15 years of WHI Study. Minerva Ginecol 2017;69:160-70. DOI: 10.23736/S0026-4784.16.04007-7

Corresponding author e-mail

ipalacios@institutopalacios.com